Efficacy of immunization of feedlot calves with a commercial Haemophilus somnus bacterin.

Two cohorts, consisting of 10,723 calves total, were identified in this prospective follow-up study to investigate whether immunization of auction market beef calves immediately upon arrival at the feedlot with a commercial Haemophilus somnus whole cell killed bacterin would reduce subsequent mortality. In addition to mortality rate, the use of incidence rate of fatal disease is introduced as an effect measure to examine vaccine efficacy in the feedlot. The Haemophilus somnus bacterin had no significant effect on the overall crude mortality rate; however, the bacterin appeared to significantly (p less than 0.05) reduce the incidence rate of fatal disease and the mortality rate during the first two months in the feedlot, when risk of fatal disease onset was highest. Once mortalities likely not associated with hemophilosis (for example, a fractured femoral neck) were removed from the analysis, steer mortality rate, but not heifer mortality rate, was reduced significantly (p less than 0.05) in the vaccinated group. The attributable percent overall for steers was 17.4%; this suggests that 17.4% of fatal respiratory disease in the unvaccinated steers could have been prevented by vaccination with the H. somnus bacterin. Heifer calves demonstrated a significantly (p less than 0.01) higher incidence rate of fatal disease during the first week than did steer calves, indicating that a different pattern of fatal disease existed for the two sexes. Use of a second vaccination two weeks after arrival did little to decrease mortality risk.     

Preliminary assessment of a Haemophilus parasuis bacterin for use in specific pathogen free swine.

A whole cell formalin killed trivalent Haemophilus parasuis bacterin was tested for efficacy in four week old, weaned specific pathogen free pigs challenged under laboratory conditions. The vaccine contained three field strains of H. parasuis selected from confirmed cases of Glasser's disease. Two different formulations were evaluated in separate trials. In trial 1, ten pigs received 5 mL of bacterin subcutaneously in the neck, followed by a second 5 mL dose two weeks later. Another ten pigs served as nonvaccinated controls. One week after the second dose, all pigs were subjected to an aerosol challenge containing the strains of H. parasuis present in the vaccine. In trial 2, a broth rather than a saline based vaccine was prepared, and tested as in trial 1. In both trials, the vaccinated pigs remained healthy postchallenge, while eight of nine (Trial 1) and eight of ten (Trial 2) nonvaccinated pigs succumbed to Glasser's disease.     

Efficacy of Bordetella bronchiseptica bacterin in controlling enzootic atrophic rhinitis in swine.

The efficacy of a Bordetella bronchiseptica bacterin was evaluated in 2 commercial swine herds affected with mild and severe enzootic atrophic rhinitis (AR). In the 1st herd study, (mild AR), the degree of clinical AR, nasal turbinate evaluation, blood serum titer to B bronchiseptica antigen, and adjusted days from birth to 100 kg were determined for individual pigs. Bacterin inoculation reduced the incidence and severity of gross turbinate atrophy 57% and reduced clinical AR over 93%. Inoculated swine had an average blood serum-agglutinating titer greater than 1:2,793 and noninoculated (control) swine had an average titer of 1:112. Increased serum titer significantly (P less than 0.05) correlated with decreased degree of nasal turbinate atrophy. Inoculated and control pigs reached 100 kg in an average of 171 and 178 days after birth, respectively. In the 2nd study (severe enzootic AR), inoculated and control pigs were individually evaluated for clinical AR and total average daily weight gain. Inoculation reduced clinical AR over 90%. The total average daily gain for the inoculated and control pits was 435.84 g and 340.50 g, respectively. Inoculated pigs and control pigs reached 100-kg market weight in 184 and 238 days, respectively.     

鸡沙门氏菌弱毒株的效力和安全试验

将鸡沙门氏菌弱毒株以不同剂量分别经口服和颈部皮下接种1日龄商品蛋鸡进行安全性和免疫效力研究,结果表明：该弱毒株对1日龄雏鸡有良好的安全性并能提供较强的保护力。     

减毒鸡沙门菌疫苗株97A的免疫保护效力试验

减毒沙门菌疫苗株97A免疫鸡经鸡沙门菌强毒株Sg9攻击后,对免疫攻毒组和攻毒对照组鸡进行病理学检查和细菌分离,以进一步评价97A疫苗的免疫保护效力。结果表明,免疫攻毒组鸡肝脏、肺脏和肾脏等实质器官仅有轻到中度的炎症反应,而攻毒对照组鸡则表现出了严重的组织病理学变化,同时减毒鸡沙门菌疫苗株97A能显著地限制强毒株在鸡体内的定居和增殖,显示出了良好的免疫保护效力。     

Efficacy of bacteriophage therapy on horizontal transmission of Salmonella gallinarum on commercial layer chickens

A Salmonella Gallinarum (SG)-specific bacteriophage isolated from sewage effluent was used to prevent horizontal transmission of SG in commercial layer chickens. Six-week-old chickens, each challenged with 5 x 10(8) colony-forming units of SG, cohabited with contact chickens treated with 10(6) plaque-forming units/kg of bacteriophage, prepared in feed additives, for 7 days before, and 21 days after challenge with SG. Mortality was observed for 3 wk after challenge and SG was periodically reisolated from the liver, spleen, and cecum of chickens. SG re-isolation from organs was decreased and a significant (P < 0.05) reduction in mortality was observed in contact chickens treated with the bacteriophage, as compared to untreated contact chickens, indicating that bacteriophage administration in feed additives significantly prevented the horizontal transmission of SG. These results provide important insights into prevention and control strategies against SG infection and suggest that the use of bacteriophages may be a novel, safe, and effectively plausible alternative to antibiotics for the prevention of SG infection in poultry.     

Efficacy of experimental inactivated mycoplasma gallisepticum oil-emulsion bacterin in egg-layer chickens

Six groups of white leghorn pullets were studied to determine the ability of beta-propiolactone-inactivated Mycoplasma gallisepticum (MG) oil-emulsion bacterins to counteract reductions in egg production caused by MG infection. The pullets were inoculated with 0.5 ml of MG bacterin subcutaneously in the neck at about 20 weeks of age and were challenged with MG near 28 weeks of age, when they were in peak egg production. Various challenge schemes with infectious bronchitis virus were used at the time of MG challenge to increase the reduction in egg production. MG bacterins afforded protection against moderate drops in egg production in at least three of the studies, where the unvaccinated challenged control hens exhibited reduced egg production.     

Efficacy of an Actinobacillus pleuropneumoniae bacterin against serotypes 1, 3, 5 and 9.

A trial was performed in a swine research facility to ascertain the protection provided by a polyvalent Actinobacillus pleuropneumoniae (APP) bacterin containing serotypes 1, 3, 5 and 9. The test animals consisted of 60, eight-week-old, piglets, which were randomly divided into four main groups. The four main groups were further divided into three sub-groups (I, II, III) of five pigs each. Subgroup I was vaccinated intramuscularly, sub-group II was vaccinated subcutaneously, and sub-group III served as the unvaccinated control group. Each main group was challenged with a single APP serotype (1, 3, 5 or 9). Criteria for evaluation of the bacterin efficacy were mortality, lung lesions, pleural adhesions, and isolation of APP from tonsil or lung. Significant effects of vaccination over nonvaccination were reduced mortality, lung lesions, pleural adhesions, and isolations of APP from tonsil and lung. There were no significant differences between the intramuscular and subcutaneous routes of vaccination. It was concluded that the four-way APP bacterin used in this study provided satisfactory protection against homologous challenge. Evidence of protection was lower mortality and lung lesions and increased daily weight gains in vaccinates as compared with controls.     

Efficacy of a trivalent Haemophilus paragallinarum vaccine compared to bivalent vaccines.

The efficacy of a trivalent oil-adjuvant Coryza vaccine containing serotypes A, B and C of Haemophilus paragallinarum has been compared with that of a bivalent oil-adjuvant Coryza vaccine containing serotypes A and C and that of a commercially available, bivalent A1(OH)3-potentiated vaccine, containing types A and C. The trivalent vaccine, given at 10 and 17 weeks of age, provided the best protection. Even at 55 weeks after booster vaccination, chickens were still significantly protected, following severe challenge with either of the three serotypes of Haemophilus paragallinarum. Both bivalent vaccines did not protect against type B challenge. Furthermore the oil-adjuvant vaccines induced higher HI-A titers, which correlate with protection, compared to the A1(OH)3-potentiated vaccine. The results show that type B strains are pathogenic and constitute a distinct immunotype and thus a Coryza vaccine should contain three serotypes to obtain a broader protection against all serotypes.     

苏皖地区副猪嗜血杆菌的分离鉴定与三价灭活疫苗的初步研制

近年来国内养猪场副猪嗜血杆菌病日益严峻,给相关猪场造成严重的损失。本研究主要对江苏省和安徽省部分养猪场的病死猪和健康猪进行副猪嗜血杆菌的分离鉴定,为副猪嗜血杆菌的防治提供流行病学数据。同时,本室初步研制副猪嗜血杆菌血清4型、5型和12型三价灭活疫苗,用BALB/c小鼠对其进行免疫保护力的评价。结果从病死猪中分离到8株副猪嗜血杆菌,其中5型3株、12型2株、14型1株及不可定型2株;从健康猪中分离到26株副猪嗜血杆菌(分离率为7.12%),其中12型10株、4型4株、11型3株、5型1株、13型1株及未定型菌株7株。初步研制的副猪嗜血杆菌三价灭活疫苗的免疫保护效果要优于商品灭活疫苗,对副猪嗜血杆菌血清4型、5型及12型具有较好的免疫保护能力。     

Efficacy of commercial Mycoplasma gallisepticum bacterin (MG-Bac) in preventing air-sac lesions in chickens

One-week-old chickens were vaccinated with commercial Mycoplasma gallisepticum bacterin subcutaneously and challenged with the S6 strain by the intra-air-sac route 3 weeks later. Significantly fewer vaccinated chickens had air-sac lesions than controls.